Johnson & Johnson started 2016 by cutting 3,000 jobs, part of a restructuring move to shore up its lagging medical device businesses. The cuts, in its orthopedics, surgery and cardiovascular units, made up 6% of its medical device employees.
Lexicon now has data from two phase 3 trials showing the effect of the SGLT1-SGLT2 inhibitor on A1C in patients with Type 1 diabetes is sustained over 52 weeks.
